Olomorasib receives FDA Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer August 5, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
IND Application for Ph 1b/2 Opamtistomig Combo in Metastatic Colorectal Cancer Approved August 5, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
Sonesitatug vedotin demonstrated statistically significant OS improvement in 2L+ CLDN18.2-positive advanced gastric/GEJ cancers July 28, 2026
FDA accepts NDA for Daraxonrasib for Review for Previously Treated Metastatic Pancreatic Cancer July 28, 2026
CTA and supply agreement between Phanes & Merck to evaluate spevatamig, KEYTRUDA & chemo combo for treatment of biliary tract cancer expanded July 28, 2026
Enrollment completed in Ph 2 trial of spevatamig + chemo for the 1L metastatic pancreatic ductal adenocarcinoma July 28, 2026
Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer July 15, 2026
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer July 15, 2026
Primary Results Announced from Ph 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs July 15, 2026
ESMO GI 2026: BOT+BAL Data Showing 33% Three-Year OS in Refractory MSS Metastatic CRC Without Active Liver Metastases July 15, 2026
FDA sends CRL for Combination of Rivoceranib and Camrelizumab as 1L Treatment for Unresectable or Metastatic HCC July 15, 2026
FDA Clears IND Application for LTZ-232 to Treat Advanced Metastatic CRC and Other Solid Tumors July 15, 2026
Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma published in Journal of Clinical Oncology (JCO) July 7, 2026
Ph 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease July 7, 2026
ESMO GI 2026: Ph 1/2 Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer Presented July 7, 2026
First patient dosed in RASolute 305 Ph 3 Trial of Zoldonrasib-Chemo combo in 1L RAS G12D Metastatic Pancreatic Cancer June 30, 2026
